Under PPACA, in every interaction between patients, doctors, insurers, manufacturers and researchers, the incentive to control costs and provide better service is replaced with the decree to do so.
The main problem with the Patient Protection and Affordable Care Act (PPACA) is that in order to extend healthcare to all citizens as a right the law undermines the fundamental free market basis (or what remains of it) of the entire U.S. medical system. Under PPACA, in every interaction between patients, doctors, insurers, manufacturers and researchers, the incentive to control costs and provide better service is replaced with the decree to do so. When the Affordable Care Act passed through Congress, Nancy Pelosi famously remarked that universal healthcare -- socialized medicine -- was becoming a reality "after 100 years of trying." It will be interesting to see therefore, whether the next 100 years of government-directed medical technology will compare favorably or otherwise with the dizzying advance of medicine during the last 100 years.
Today, ninety-five percent of the new drugs coming on the market are developed for sale in the United States. For years, according to a study in Nature Reviews Drug Discovery, pharmaceutical companies in Western Europe have been introducing new medicines in the U.S. before introducing them in their home countries; typically by eighteen months. This is due to regulation of drug prices in Europe that makes recuperation of R&D costs (a very high 20% of revenues in the pharmaceutical industry) impossible there.
Read the full story here: http://bit.ly/1aO72u1
Source: American Thinker
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for Health and Human Services (HHS) leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More